Alcon is the world's largest eye care device company, founded in 1945 and now operating across 60 countries to serve patients in more than 140. The company develops surgical equipment, vision correction devices, pharmaceutical treatments, and diagnostic technologies across the full spectrum of ophthalmology.
The company invests over $876 million annually in research and development, with more than 70 products currently under development. Its portfolio includes AcrySof intraocular lenses and DAILIES TOTAL1 contact lenses, alongside a broader range of solutions for cataract surgery, refractive surgery, retinal disease, and dry eye treatment.
Alcon's scale and investment intensity reflect its position as a primary innovator in eye care devices and pharmaceuticals. The company's operating model centres on addressing unmet clinical needs through research-backed product development, supported by extensive manufacturing and distribution networks that reach ophthalmologists and patients worldwide.
